Bristol-Myers Squibb Company
Therapeutic TREM-1 peptides
Last updated:
Abstract:
A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
Status:
Grant
Type:
Utility
Filling date:
14 Dec 2015
Issue date:
31 Mar 2020